玻璃酸钠联合复方倍他米松注射液治疗膝关节骨性关节炎的临床疗效观察

《玻璃酸钠联合复方倍他米松注射液治疗膝关节骨性关节炎的临床疗效观察》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、珈獰顒关牺縮瞰节骨岐节2018-03-2910:29:58中国现代医生2018年6期朱鑫鑫沈金明［摘要］戸的探討玻璃酸钠联合复方倍他米松注射液治疗膝关节骨性关节炎的临床疗效。方法收集2016年1月〜2017年1月我院收治的膝关节骨性关节炎患者90例作为研究对象，将纳入符合要求患者采用随机数字表法随机分成观察组(n=45)和对照组(n=45)。两组均予以玻璃酸钠关节腔内注射，观察组同时加入复方倍他米松注射液，两组均治疗5周。治疗后对两组的临床疗效、临床症状改善情况及膝关节功能改善情况进行评价。结果观察组患者治疗后的总有效率(

2、97.8%)明显高于对照组(77.8%),差异有统计学意义(P<0.05)。两组患者治疗前的HSS评分比较，差异无统计学意义(P>0.05)；治疗后HSS评分与治疗前比较明显升高(P<0.05),观察组患者治疗后HSS评分显著高于对照组，差异有统计学意义(P<0.05)。两组患者治疗前的临床症状评分比较，差异无统计学意义(P>0.05),治疗后两组患者临床症状评分较治疗前明显降低(PvO.05),且观察组患者治疗后的临床症状评分显著低于对照组，差异有统计学意义(PvO.05)。结论玻璃酸钠联合复方倍他米松注射液治疗膝关节骨

3、性关节炎临床疗效显著提高，且患者的临床症状明显改善，膝关节功能明显提高，值得广泛推广和应用。［关键词］膝关节骨性关节炎；玻璃酸钠；复方倍他米松注射液；HSS评分［中图分类号］R684.3［文献标识码］B［文章编1673-9701(2018)06-0090-04［Abstract］ObjectiveToinvestigatetheclinicalefficacyofsodiumhyaluronatecombinedwithcompoundbetamethasoneinjectioninthetreatmentofkneeos

4、teoarthritis・MethodsAtotalof90patientswithkneeosteoarthritiswhowereadmittedtoourhospitalfromJanuary2016toJanuary2017werecollectedasthestudysubjects.Patientswhowereeligibleforinclusionwererandomlydividedintoobservationgroup(n二45)andcontrolgroup(n=45)viarandomnumber

5、table.Thetwogroupsweregivensodiumhyaluronateintra-articularinjection.Theobservationgroupwasalsogivencompoundbetamethasoneinjection.Bothgroupsweretreatedfor5weeks.Aftertreatment,theclinicalefficacy,improvementofclinicalsymptomsandimprovementofkneejointfunctionweree

6、valuatedinbothgroups・ResultsThetotaleffectiverate(97.8%)inobservationgroupwassignificantlyhigherthanthatincontrolgroup(77.8%),andthecomparativeanalysisoftheefficacyinthetwogroupsshowedsignificantdifferences(P<0.05)・TherewasnostatisticallysignificantdiffereneeinHSS

7、scoresbetweenthetwogroupsbeforetreatment(P>0.05)；aftertreatment,HSSscorewassignificantlyhigherthanthatbeforetreatment(P<0・05)；theHSSscoreintheobservationgroupwassignificantlyhigherthanthatinthecontrolgroupaftertreatment,andthecomparativeanalysisinthetwogroupsshowe

8、dsignificantdifferences(P<0.05).Therewasnostatisticallysignificantdifferenceinclinicalsymptomscoresbetweenthetwogroupsbeforetreatment(P>0.05)；thescoresa